Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ⅰ Study to Evaluate the Safety/Tolerability, Pharmacokinetics, and Efficacy of SC-101 in Subjects With Advanced or Metastatic Solid Tumors That Express Nectin-4

NCT06220838 is registered in ClinicalTrials.gov with Tianjin ConjuStar Biologics Co., Ltd. as lead sponsor.

NCT NCT06220838
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06220838 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ⅰ Study to Evaluate the Safety/Tolerability, Pharmacokinetics, and Efficacy of SC-101 in Subjects With Advanced or Metastatic Solid Tumors That Express Nectin-4
Lead sponsor
Tianjin ConjuStar Biologics Co., Ltd.
Phase
Phase 1
Overall status
Recruiting
Start date
February 2, 2024
Completion date
September 30, 2026
Enrollment
100 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor